Incidence of Dyslipidemia in People With HIV Who Are Treated With Integrase Inhibitors Versus Other Antiretroviral Agents: The RESPOND Study Group

Dathan M. Byonanebye; Mark N. Polizzotto; Josip Begovac; Katharina Grabmeier-Pfistershammer; Irene Abela; Antonella Castagna; Stéphane DeWit; Cristina Mussini; Jörg J. Vehreschild; Antonella d'A Monforte; Ferdinand W.N.M. Wit; Christian Pradier; Nikoloz Chkhartishvili; Anders Sönnerborg; Jennifer Hoy; Jens Lundgren; Bastian Neesgaard; Loveleen Bansi-matharu; Lauren Greenberg; Josep M. Llibre; Vani Vannappagari; Joel Gallant; Coca Necsoi; Piotr Cichon; Peter Reiss; Inka Aho; Tengiz Tsertsvadze; Marianna Mennozzi; Andri Rauch; Camilla Muccini; Matthew Law; Amanda Mocroft; Lene Ryom; Kathy Petoumenos

Disclosures

AIDS. 2021;35(6):869-882. 

In This Article

Conclusion

In this consortium of heterogeneous cohorts, the incidence of dyslipidemia in PLWH taking ART was high. The incidence in PLWH taking INSTI was lower than in PLWH taking PI/b and higher in those taking NNRTI. Compared with DTG, dyslipidemia was less common in PLWH taking RPV, but more common in participants treated with EVG/c or RAL. Due to higher efficacy, INSTI-based regimens could remain the ART of choice even in PLWH with high dyslipidemia. RPV could be considered as an ART option in PLWH with suppressed HIV RNA who are intolerant to INSTI. PLWH with traditional CVD risk factors and those taking PI/b should be monitored and offered lifestyle counseling.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....